We are live on ! Find out more
MTNB icon

Matinas BioPharma
MTNB

45 hedge funds and large institutions have $18M invested in Matinas BioPharma in 2017 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

371% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 7

156% more capital invested

Capital invested by funds: $7.01M → $18M (+$10.9M)

137% more funds holding

Funds holding: 19 → 45 (+26)

25% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 4

0.15% more ownership

Funds ownership: 0.09% → 0.23% (+0.15%)

Holders
45
Holders Change
+26
Holders Change %
+136.84%
% of All Funds
1.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
33
Increased
5
Reduced
4
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$6.57M
2
BlackRock
BlackRock
New York
+$6.43M
3
IA
IFP Advisors
Florida
+$1.88M
4
State Street
State Street
Massachusetts
+$1.79M
5
Northern Trust
Northern Trust
Illinois
+$1.56M

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$691K
2
Goldman Sachs
Goldman Sachs
New York
-$566K
3
SCM
Segantii Capital Management
Hong Kong
-$166K
4
Morgan Stanley
Morgan Stanley
New York
-$157K
5
SIM
Spark Investment Management
New York
-$105K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$4.13M +$6.57M +48,940 New
BlackRock
2
BlackRock
New York
$4.05M +$6.43M +47,929 New
IA
3
IFP Advisors
Florida
$1.18M +$1.88M +14,000 New
State Street
4
State Street
Massachusetts
$1.13M +$1.79M +13,342 New
RJFSA
5
Raymond James Financial Services Advisors
Florida
$1.09M +$11.5K +86 +0.7%
Northern Trust
6
Northern Trust
Illinois
$980K +$1.56M +11,586 New
Geode Capital Management
7
Geode Capital Management
Massachusetts
$836K +$1.33M +9,904 New
Royal Bank of Canada
8
Royal Bank of Canada
Ontario, Canada
$775K +$335K +2,495 +37%
AWMG
9
Alliance Wealth Management Group
New Jersey
$677K – – –
VKH
10
Virtu KCG Holdings
New York
$408K +$462K +3,443 +248%
Bank of New York Mellon
11
Bank of New York Mellon
New York
$282K +$447K +3,331 New
TCIM
12
TIAA CREF Investment Management
New York
$247K +$392K +2,918 New
BCM
13
Bridgeway Capital Management
Texas
$211K +$336K +2,500 New
TA
14
Teachers Advisors
New York
$163K +$259K +1,927 New
California State Teachers Retirement System (CalSTRS)
15
California State Teachers Retirement System (CalSTRS)
California
$158K +$251K +1,870 New
Charles Schwab
16
Charles Schwab
California
$152K +$240K +1,790 New
AA
17
ALPS Advisors
Colorado
$139K +$222K +1,650 New
CDH
18
Charles D. Hyman
$135K – – –
Deutsche Bank
19
Deutsche Bank
Germany
$101K +$162K +1,205 New
New York State Common Retirement Fund
20
New York State Common Retirement Fund
New York
$95K +$151K +1,122 New
Millennium Management
21
Millennium Management
New York
$86K -$691K -5,148 -84%
RhumbLine Advisers
22
RhumbLine Advisers
Massachusetts
$86K +$136K +1,016 New
Morgan Stanley
23
Morgan Stanley
New York
$85K -$157K -1,167 -54%
JP Morgan Chase
24
JP Morgan Chase
New York
$76K +$121K +900 New
IIA
25
IPG Investment Advisors
California
$66.8K +$13.4K +100 +14%
1
2 3

MTNB Hedge Fund Activity: Q2 2017 in Review

45 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q2 2017, worth a combined $18M — up 156% from $7.01M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new MTNB positions and 7 closed out — a net gain of 26 holders — while 5 added to existing stakes and 4 trimmed.

The largest buyer was Vanguard Group, opening a new position worth an estimated $6.57M. The largest seller was Millennium Management, cutting an estimated $691K.

  • 45 institutional investors held Matinas BioPharma (MTNB) as of Q2 2017, up from 19 in Q1 2017.
  • Funds reported $18M of Matinas BioPharma stock for Q2 2017, up 156% quarter-over-quarter.
  • 33 funds opened new Matinas BioPharma positions in Q2 2017 and 7 closed out, a net change of +26 holders.
  • The largest Matinas BioPharma buyer in Q2 2017 was Vanguard Group, an estimated $6.57M added.
  • The largest Matinas BioPharma seller in Q2 2017 was Millennium Management, an estimated $691K sold.

Based on aggregated 13F filings for Q2 2017.